| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Aaron Ciechanover | Q233205 |
| Lilach O. Lerman | Q77286570 | ||
| Amir Lerman | Q77286771 | ||
| Joerg Herrmann | Q99344983 | ||
| P433 | issue | 1 | |
| P921 | main subject | cardiovascular disease | Q389735 |
| ubiquitin-proteasome system | Q47175589 | ||
| P304 | page(s) | 11-21 | |
| P577 | publication date | 2004-01-01 | |
| P1433 | published in | Cardiovascular Research | Q4642329 |
| P1476 | title | The ubiquitin-proteasome system in cardiovascular diseases-a hypothesis extended | |
| P478 | volume | 61 |
| Q39197422 | 15-Deoxy-Δ12,14-Prostaglandin J2 Modifies Components of the Proteasome and Inhibits Inflammatory Responses in Human Endothelial Cells |
| Q24297364 | A functional SNP in PSMA6 confers risk of myocardial infarction in the Japanese population |
| Q36378766 | A soluble ATP-dependent proteolytic system is responsible for protein degradation |
| Q61798731 | ACE Insertion/Deletion Polymorphism (rs4646994) Is Associated With the Increased Risk of Multiple Myeloma |
| Q34594355 | Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib |
| Q40411990 | Adeno-associated virus (AAV)-7 and -8 poorly transduce vascular endothelial cells and are sensitive to proteasomal degradation. |
| Q28570709 | Adhesion-dependent Skp2 transcription requires selenocysteine tRNA gene transcription-activating factor (STAF) |
| Q28578102 | An essential role of PDCD4 in vascular smooth muscle cell apoptosis and proliferation: implications for vascular disease |
| Q36445136 | Angiotensin II as candidate of cardiac cachexia |
| Q41942054 | Association between functional variant of inflammatory system gene (PSMA6) and end-stage kidney disease |
| Q49722917 | Bioinformatic Analysis of Coronary Disease Associated SNPs and Genes to Identify Proteins Potentially Involved in the Pathogenesis of Atherosclerosis |
| Q36630651 | Bortezomib alleviates drug-induced liver injury by regulating CYP2E1 gene transcription |
| Q50484704 | Bortezomib enhances fatty liver preservation in Institut George Lopez-1 solution through adenosine monophosphate activated protein kinase and Akt/mTOR pathways. |
| Q37711394 | Bortezomib-induced Severe Congestive Heart Failure. |
| Q36756282 | Breaking down protein degradation mechanisms in cardiac muscle |
| Q36057480 | Cardiac Nav 1.5 is modulated by ubiquitin protein ligase E3 component n-recognin UBR3 and 6. |
| Q37061596 | Cardiac toxicity: old and new issues in anti-cancer drugs. |
| Q36068716 | Changes in expression of proteasome in rats at different stages of atherosclerosis |
| Q80610675 | Clinical significance of single nucleotide polymorphisms in PCSK9 |
| Q36054446 | Clinical, molecular, and genomic changes in response to a left ventricular assist device |
| Q43129743 | Diallyl disulfide and diallyl trisulfide protect endothelial nitric oxide synthase against damage by oxidized low-density lipoprotein |
| Q35659471 | Dysfunction of the ubiquitin-proteasome system in atherosclerotic cardiovascular disease |
| Q46722579 | Effects of ubiquitin-proteasome system deregulation on the vascular senescence and atherosclerosis process in elderly patients |
| Q36204680 | Enhancement of 26S proteasome functionality connects oxidative stress and vascular endothelial inflammatory response in diabetes mellitus |
| Q38676071 | FAT10 protein binds to polyglutamine proteins and modulates their solubility |
| Q30176404 | FBXO44-Mediated Degradation of RGS2 Protein Uniquely Depends on a Cullin 4B/DDB1 Complex. |
| Q36225104 | From organ to molecules: steps and consequences |
| Q35963030 | Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia |
| Q36025929 | Inflammation, blood pressure, and stroke: an opportunity to target primary prevention? |
| Q36217025 | Inhibition of Proteasome Activity by Low-dose Bortezomib Attenuates Angiotensin II-induced Abdominal Aortic Aneurysm in Apo E(-/-) Mice |
| Q34085529 | Integrated statistical and pathway approach to next-generation sequencing analysis: a family-based study of hypertension |
| Q42577380 | Involvement of the ubiquitin-proteasome system in the formation of experimental postsurgical peritoneal adhesions |
| Q53516074 | Links between mTOR and the immunoproteasome: Therapeutic targets for cardiac hypertrophy? |
| Q38227386 | NF-κB signaling at the crossroads of inflammation and atherogenesis: searching for new therapeutic links |
| Q35602473 | Nitric oxide affects UbcH10 levels differently in type 1 and type 2 diabetic rats |
| Q33554513 | On to the road to degradation: atherosclerosis and the proteasome |
| Q36589368 | Oxidative stress as the leading cause of acute myocardial infarction in diabetics |
| Q33717656 | Phosphorylation of VACM-1/Cul5 by protein kinase A regulates its neddylation and antiproliferative effect |
| Q38239855 | Pneumocyte injury and ubiquitin-positive pneumocytes in interstitial lung diseases |
| Q36865776 | Primary proteasome inhibition results in cardiac dysfunction |
| Q44226026 | Proteasome Inhibitor Reduces Astrocytic iNOS Expression and Functional Deficit after Experimental Intracerebral Hemorrhage in Rats |
| Q57821113 | Proteasome biology and therapeutics in cardiac diseases |
| Q39976598 | Proteasome inhibition attenuates coxsackievirus-induced myocardial damage in mice |
| Q44409970 | Proteasome inhibitor PS-341 attenuates flow-induced pulmonary arterial hypertension |
| Q47161331 | Proteasome-associated deubiquitinases and cancer |
| Q39313701 | Protein Expression by Human Pulmonary Artery Smooth Muscle Cells Containing a BMPR2 Mutation and the Action of ET-1 as Determined by Proteomic Mass Spectrometry. |
| Q33337003 | Proteomic analysis permits the identification of new biomarkers of arterial wall remodeling in hypertension |
| Q37608861 | Proteomic identification of protein ubiquitination events |
| Q46261037 | Quantitative assessment of the influence of PSMA6 variant (rs1048990) on coronary artery disease risk |
| Q92582478 | RING finger protein 10 is a potential drug target for diabetic vascular complications |
| Q39643768 | Resveratrol enhances anti-proliferative effect of VACM-1/cul5 in T47D cancer cells |
| Q35951259 | Seven-transmembrane receptors and ubiquitination |
| Q30814901 | Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report |
| Q85208809 | Suramin inhibits the development and progression of peritoneal fibrosis |
| Q41884603 | Systemic inflammation as a predictor of clinical outcomes after lower extremity angioplasty/stenting |
| Q35045905 | Taking pressure off the heart: the ins and outs of atrophic remodelling |
| Q34195083 | Targeting the ubiquitin-proteasome pathway with inorganic compounds to fight cancer: a challenge for the future |
| Q57611309 | The exon 1–8C/G SNP in the PSMA6 gene contributes only a small amount to the burden of myocardial infarction in 6946 cases and 2720 controls from a United Kingdom population |
| Q33344790 | The possible role of the ubiquitin proteasome system in the development of atherosclerosis in diabetes. |
| Q36571678 | The proteasome inhibitor lactacystin attenuates growth and migration of vascular smooth muscle cells and limits the response to arterial injury |
| Q36721779 | The role of allostery in the ubiquitin-proteasome system |
| Q38107999 | The role of ubiquitin-proteasome system in glioma survival and growth |
| Q33816688 | The ubiquitin proteasome system in human cardiomyopathies and heart failure |
| Q36538328 | The ubiquitin-proteasome pathway in viral infections |
| Q27021582 | The ubiquitin-proteasome system and cardiovascular disease |
| Q36194796 | The ubiquitin-proteasome system--micro target for macro intervention? |
| Q53495126 | The ubiquitin-proteasome system: a novel target for anticancer and anti-inflammatory drug research. |
| Q28082910 | Trial Watch: Proteasomal inhibitors for anticancer therapy |
| Q91648896 | UBC9 regulates cardiac sodium channel Nav1.5 ubiquitination, degradation and sodium current density |
| Q34399689 | Ubiquitin-activating enzyme E1 inhibitor PYR41 attenuates angiotensin II-induced activation of dendritic cells via the IκBa/NF-κB and MKP1/ERK/STAT1 pathways |
| Q37820063 | Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets |
| Q37587303 | Upregulation of proteasome activity rescues cardiomyocytes following pulse treatment with a proteasome inhibitor |
| Q34031947 | VACM-1/cul5 expression in vascular tissue in vivo is induced by water deprivation and its expression in vitro regulates aquaporin-1 concentrations |
Search more.